Genmab (GMAB) executives acquire shares through restricted stock unit vesting
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Genmab A/S filed a Form 6-K detailing routine equity compensation events for several senior leaders. On April 1, 2026, restricted stock units vested into Genmab shares for President & CEO Jan van de Winkel, CFO Anthony Pagano and four other executive vice presidents. Each transaction is reported as an acquisition of shares due to vesting of restricted stock units, conducted outside the market at a reference price of DKK 1,758.50 per share. The filing is also incorporated by reference into Genmab’s existing Form S-8 registration statements.
Positive
- None.
Negative
- None.
Key Figures
CEO RSU vesting: 8,525 shares at DKK 1,758.50
CFO RSU vesting: 4,206 shares at DKK 1,758.50
Strategy EVP RSU vesting: 439 shares at DKK 1,758.50
+3 more
6 metrics
CEO RSU vesting
8,525 shares at DKK 1,758.50
Acquisition by Jan van de Winkel on April 1, 2026
CFO RSU vesting
4,206 shares at DKK 1,758.50
Acquisition by Anthony Pagano on April 1, 2026
Strategy EVP RSU vesting
439 shares at DKK 1,758.50
Acquisition by Martine van Vugt on April 1, 2026
Chief Medical Officer RSU vesting
5,186 shares at DKK 1,758.50
Acquisition by Tahamtan Ahmadi on April 1, 2026
Chief People Officer RSU vesting
2,825 shares at DKK 1,758.50
Acquisition by Christopher Cozic on April 1, 2026
Chief Development Officer RSU vesting
4,744 shares at DKK 1,758.50
Acquisition by Judith Klimovsky on April 1, 2026
Key Terms
restricted stock units, Market Abuse, vesting, forward looking statements, +2 more
6 terms
restricted stock units financial
"The transactions concern vesting of restricted stock units and further details are set out"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Market Abuse regulatory
"In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse, Genmab A/S publishes"
Market abuse is illegal or unethical behavior that distorts the price or fairness of buying and selling financial assets, such as using secret information to trade, spreading false or misleading news, or creating fake buying and selling to give a false impression of demand. It matters to investors because it can cause unfair losses, unreliable prices and legal or reputational fallout; like cheating in a game or tampering with a scale, it destroys confidence that markets reflect true value.
vesting financial
"The transactions concern vesting of restricted stock units and further details are set out"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
forward looking statements regulatory
"The Company Announcement contains forward looking statements. The words “believe,” “expect,”"
Statements about a company’s expected future performance, plans, goals, or projections that are not historical facts and involve assumptions and estimates. Investors care because these are predictions that guide decisions but can be wrong; like a weather forecast, they help set expectations and risk — if circumstances change, actual results may differ significantly, so investors should weigh them alongside hard data and risk factors.
antibody–drug conjugates medical
"therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating"
bispecific antibodies medical
"advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug"
Engineered proteins that can attach to two different biological targets at once, like a two-headed key that fits two locks simultaneously; in medicine they often link immune cells to diseased cells or block two disease pathways at the same time. Investors care because this dual-action design can improve effectiveness or open new treatment options, but it also raises development complexity, manufacturing cost and regulatory risk, affecting a biotech company’s value and partnerships.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE MONTH OF APRIL 2026
COMMISSION FILE NUMBER 001-38976
Genmab A/S
(Exact name of Registrant as specified in its charter)
(Exact name of Registrant as specified in its charter)
Carl Jacobsens Vej 30
2500 Valby
Denmark
+45 70 20 27 28
(Address of principal executive offices)
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F Form 40-F
This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273, 333-284876 and 333-293505) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
| Exhibit | Description of Exhibit | ||||
| 99.1 | Company Announcement Dated April 1, 2026: Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons | ||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| GENMAB A/S | ||||||||
| BY: | /s/ Anthony Pagano | |||||||
| Name: Anthony Pagano | ||||||||
| Title: Executive Vice President & Chief Financial Officer | ||||||||
DATE: APRIL 1, 2026
Exhibit 99.1
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Company Announcement
COPENHAGEN, Denmark; April 1, 2026 – Genmab A/S (Nasdaq: GMAB) - This document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.
In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse, Genmab A/S publishes transactions in shares and linked securities issued by Genmab A/S by managerial employees and their closely associated persons. The transactions concern vesting of restricted stock units and further details are set out in the tables below.
This company announcement includes the vesting and net settlement of the restricted stock units granted to Jan van de Winkel and Anthony Pagano on March 29, 2023.
Please find below a statement of such trading in shares issued by Genmab A/S
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |||||||||||||
| a) | Name | Jan van de Winkel | ||||||||||||
| 2. | Reason for the notification | |||||||||||||
| a) | Position/status | President & Chief Executive Officer | ||||||||||||
| b) | Initial notification/Amendment | Initial notification | ||||||||||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||
| a) | Name | Genmab A/S | ||||||||||||
| b) | LEI-code | 529900MTJPDPE4MHJ122 | ||||||||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||||||
| a) | Description of the financial instrument, type of instrument Identification code | Share DK0010272202 | ||||||||||||
| b) | Nature of the transaction | Acquisition due to vesting of restricted stock units | ||||||||||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||||||||||
DKK 1,758.50 | 8,525 | |||||||||||||
| d) | Aggregated information - Aggregated volume - Price | 8,525 shares DKK 1,758.50 | ||||||||||||
| e) | Date of the transaction | 2026-04-01 | ||||||||||||
| f) | Place of the transaction | Outside the market | ||||||||||||
| Genmab A/S Carl Jacobsens Vej 30 2500 Valby, Denmark | Tel: +45 7020 2728 www.genmab.com | Company Announcement no. 21 Page 1/7 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 | ||||||
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |||||||||||||
| a) | Name | Anthony Pagano | ||||||||||||
| 2. | Reason for the notification | |||||||||||||
| a) | Position/status | Executive Vice President & Chief Financial Officer | ||||||||||||
| b) | Initial notification/Amendment | Initial notification | ||||||||||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||
| a) | Name | Genmab A/S | ||||||||||||
| b) | LEI-code | 529900MTJPDPE4MHJ122 | ||||||||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||||||
| a) | Description of the financial instrument, type of instrument Identification code | Share DK0010272202 | ||||||||||||
| b) | Nature of the transaction | Acquisition due to vesting of restricted stock units | ||||||||||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||||||||||
1,758.50 | 4,206 | |||||||||||||
| d) | Aggregated information - Aggregated volume - Price | 4,206 shares DKK 1,758.50 | ||||||||||||
| e) | Date of the transaction | 2026-04-01 | ||||||||||||
| f) | Place of the transaction | Outside the market | ||||||||||||
| Genmab A/S Carl Jacobsens Vej 30 2500 Valby, Denmark | Tel: +45 7020 2728 www.genmab.com | Company Announcement no. 21 Page 2/7 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 | ||||||
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |||||||||||||
| a) | Name | Martine van Vugt | ||||||||||||
| 2. | Reason for the notification | |||||||||||||
| a) | Position/status | Executive Vice President & Chief Strategy Officer | ||||||||||||
| b) | Initial notification/Amendment | Initial notification | ||||||||||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||
| a) | Name | Genmab A/S | ||||||||||||
| b) | LEI-code | 529900MTJPDPE4MHJ122 | ||||||||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||||||
| a) | Description of the financial instrument, type of instrument Identification code | Share DK0010272202 | ||||||||||||
| b) | Nature of the transaction | Acquisition due to vesting of restricted stock units | ||||||||||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||||||||||
1,758.50 | 439 | |||||||||||||
| d) | Aggregated information - Aggregated volume - Price | 439 shares DKK 1,758.50 | ||||||||||||
| e) | Date of the transaction | 2026-04-01 | ||||||||||||
| f) | Place of the transaction | Outside the market | ||||||||||||
| Genmab A/S Carl Jacobsens Vej 30 2500 Valby, Denmark | Tel: +45 7020 2728 www.genmab.com | Company Announcement no. 21 Page 3/7 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 | ||||||
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |||||||||||||
| a) | Name | Tahamtan Ahmadi | ||||||||||||
| 2. | Reason for the notification | |||||||||||||
| a) | Position/status | Executive Vice President & Chief Medical Officer | ||||||||||||
| b) | Initial notification/Amendment | Initial notification | ||||||||||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||
| a) | Name | Genmab A/S | ||||||||||||
| b) | LEI-code | 529900MTJPDPE4MHJ122 | ||||||||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||||||
| a) | Description of the financial instrument, type of instrument Identification code | Share DK0010272202 | ||||||||||||
| b) | Nature of the transaction | Acquisition due to vesting of restricted stock units | ||||||||||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||||||||||
1,758.50 | 5,186 | |||||||||||||
| d) | Aggregated information - Aggregated volume - Price | 5,186 shares DKK 1,758.50 | ||||||||||||
| e) | Date of the transaction | 2026-04-01 | ||||||||||||
| f) | Place of the transaction | Outside the market | ||||||||||||
| Genmab A/S Carl Jacobsens Vej 30 2500 Valby, Denmark | Tel: +45 7020 2728 www.genmab.com | Company Announcement no. 21 Page 4/7 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 | ||||||
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |||||||||||||
| a) | Name | Christopher Cozic | ||||||||||||
| 2. | Reason for the notification | |||||||||||||
| a) | Position/status | Executive Vice President & Chief People Officer | ||||||||||||
| b) | Initial notification/Amendment | Initial notification | ||||||||||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||
| a) | Name | Genmab A/S | ||||||||||||
| b) | LEI-code | 529900MTJPDPE4MHJ122 | ||||||||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||||||
| a) | Description of the financial instrument, type of instrument Identification code | Share DK0010272202 | ||||||||||||
| b) | Nature of the transaction | Acquisition due to vesting of restricted stock units | ||||||||||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||||||||||
1,758.50 | 2,825 | |||||||||||||
| d) | Aggregated information - Aggregated volume - Price | 2,825 shares DKK 1,758.50 | ||||||||||||
| e) | Date of the transaction | 2026-04-01 | ||||||||||||
| f) | Place of the transaction | Outside the market | ||||||||||||
| Genmab A/S Carl Jacobsens Vej 30 2500 Valby, Denmark | Tel: +45 7020 2728 www.genmab.com | Company Announcement no. 21 Page 5/7 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 | ||||||
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |||||||||||||
| a) | Name | Judith Klimovsky | ||||||||||||
| 2. | Reason for the notification | |||||||||||||
| a) | Position/status | Executive Vice President & Chief Development Officer | ||||||||||||
| b) | Initial notification/Amendment | Initial notification | ||||||||||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||
| a) | Name | Genmab A/S | ||||||||||||
| b) | LEI-code | 529900MTJPDPE4MHJ122 | ||||||||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||||||
| a) | Description of the financial instrument, type of instrument Identification code | Share DK0010272202 | ||||||||||||
| b) | Nature of the transaction | Acquisition due to vesting of restricted stock units | ||||||||||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||||||||||
1,758.50 | 4,744 | |||||||||||||
| d) | Aggregated information - Aggregated volume - Price | 4,744 shares DKK 1,758.50 | ||||||||||||
| e) | Date of the transaction | 2026-04-01 | ||||||||||||
| f) | Place of the transaction | Outside the market | ||||||||||||
About Genmab
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.
Contact:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
| Genmab A/S Carl Jacobsens Vej 30 2500 Valby, Denmark | Tel: +45 7020 2728 www.genmab.com | Company Announcement no. 21 Page 6/7 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 | ||||||
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
The Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in the Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®.
| Genmab A/S Carl Jacobsens Vej 30 2500 Valby, Denmark | Tel: +45 7020 2728 www.genmab.com | Company Announcement no. 21 Page 7/7 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 | ||||||
FAQ
What does Genmab (GMAB) disclose in this April 2026 Form 6-K?
Genmab discloses equity transactions for several senior executives. These are acquisitions of Genmab shares resulting from the vesting and net settlement of previously granted restricted stock units, reported in line with Article 19 of the Market Abuse Regulation.
What RSU vesting did Genmab CFO Anthony Pagano report?
Executive Vice President & CFO Anthony Pagano acquired 4,206 Genmab shares due to the vesting of restricted stock units at DKK 1,758.50 per share. The Form 6-K notes the transaction occurred on April 1, 2026, outside the market as a compensation-related event.
Which other Genmab (GMAB) executives had RSUs vest on April 1, 2026?
RSUs vested into Genmab shares for Executive Vice Presidents Martine van Vugt, Tahamtan Ahmadi, Christopher Cozic and Judith Klimovsky. Each is reported as acquiring shares in Genmab A/S through RSU vesting on April 1, 2026, outside the market.
How is this Genmab RSU vesting information linked to U.S. registrations?
The Form 6-K states it is incorporated by reference into Genmab’s Form S-8 registration statements. This means the disclosed RSU-related share transactions form part of the disclosure record supporting Genmab’s existing equity compensation plans registered in the United States.